6RC Stock Overview
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ReproCELL Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.61 |
| 52 Week High | JP¥2.12 |
| 52 Week Low | JP¥0.60 |
| Beta | 0.37 |
| 1 Month Change | -12.77% |
| 3 Month Change | -39.11% |
| 1 Year Change | -61.32% |
| 3 Year Change | -78.94% |
| 5 Year Change | -66.36% |
| Change since IPO | -95.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6RC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.1% | -1.5% | 1.9% |
| 1Y | -61.3% | -23.6% | 4.6% |
Return vs Industry: 6RC underperformed the German Biotechs industry which returned -23.6% over the past year.
Return vs Market: 6RC underperformed the German Market which returned 4.6% over the past year.
Price Volatility
| 6RC volatility | |
|---|---|
| 6RC Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6RC's share price has been volatile over the past 3 months.
Volatility Over Time: 6RC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 92 | Shuji Yokoyama | www.reprocell.com |
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, and synfire induced neurons; 3D cell culture; and labware. The company also provides research stem cell, genomics, clinical stem cell research, preclinical and drug discovery CRO, precision medicine, human tissue samples, clinical laboratory, diagnostic, and gene editing services.
ReproCELL Incorporated Fundamentals Summary
| 6RC fundamental statistics | |
|---|---|
| Market cap | €72.57m |
| Earnings (TTM) | -€1.30m |
| Revenue (TTM) | €14.95m |
4.9x
P/S Ratio-55.8x
P/E RatioIs 6RC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6RC income statement (TTM) | |
|---|---|
| Revenue | JP¥2.51b |
| Cost of Revenue | JP¥1.42b |
| Gross Profit | JP¥1.09b |
| Other Expenses | JP¥1.31b |
| Earnings | -JP¥218.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | -2.44 |
| Gross Margin | 43.50% |
| Net Profit Margin | -8.70% |
| Debt/Equity Ratio | 0% |
How did 6RC perform over the long term?
See historical performance and comparison